This is consistent with studies showing strikingly high frequencies of MYD88 mutations in primary CNS lymphoma, as well as an increased risk of CNS recurrence in systemic de novo DLBCL patients carrying the MYD88 L265P mutation, particularly in the MCD genetic subtype [21, 22]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.